低剂量率近距离放疗推量在不利风险前列腺癌中的使用与生存
基于美国国家癌症数据库2004–2012年25038例接受雄激素抑制联合放疗的不利风险前列腺癌男性,低剂量率近距离放疗推量(LDR-B)使用比例从29%降至14%。LDR-B推量组总生存优于单纯剂量递增外照射放疗(DE-EBRT)组,倾向评分匹配后仍显示生存获益;作者认为LDR-B推量可能是不利风险前列腺癌的理想治疗选择,但需等待随机试验长期结果。
要点
- 2004–2012年LDR-B推量使用比例从29%降至14%。
- LDR-B推量组7年总生存82% vs DE-EBRT组73%(p<0.001)。
- 多因素分析LDR-B推量与更好总生存相关(HR 0.70,95%CI 0.64–0.77)。
核心结论
- 2004–2012年间LDR-B推量使用率下降,与单纯DE-EBRT相比与更好的总生存相关。
- 作者认为LDR-B推量可能是不利风险前列腺癌的理想治疗选择,但需等待随机试验的长期结果。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2004–2012年接受雄激素抑制联合放疗的不利风险前列腺癌男性25038例。
- 比较EBRT后LDR-B推量组与单纯剂量递增外照射放疗(75.6–86.4Gy)组的总生存。
主要发现
- 2004–2012年间LDR-B推量使用比例从29%降至14%。
- 单因素分析7年总生存LDR-B推量组82% vs DE-EBRT组73%(p<0.001)。
- 多因素分析LDR-B推量与更好总生存相关(HR 0.70,95%CI 0.64–0.77)。
- 倾向评分匹配验证LDR-B推量相关总生存获益(HR 0.74,95%CI 0.66–0.89)。
- 限定于年龄<60岁且无合并症男性时,LDR-B推量的总生存获益持续存在;亚组分析中治疗与年龄、风险组或放疗剂量无交互作用。
关键数值与推荐
- LDR-B推量组7年总生存82% vs DE-EBRT组73%(p<0.001)。
- 多因素分析中LDR-B推量 vs DE-EBRT的HR 0.70(95%CI 0.64–0.77)。
- 倾向评分匹配后LDR-B推量 vs DE-EBRT的HR 0.74(95%CI 0.66–0.89)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为LDR-B推量可能是不利风险前列腺癌的理想治疗选择,但需等待随机试验的长期结果。
局限性
- 回顾性设计。
- 非随机选择偏倚。
- 缺乏治疗毒性、激素持续时间及肿瘤特异性结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited comparative survival data for prostate cancer (PCa) patients managed with a low-dose rate brachytherapy (LDR-B) boost and dose-escalated external-beam radiotherapy (DE-EBRT) alone. OBJECTIVE: To compare overall survival (OS) for men with unfavorable PCa between LDR-B and DE-EBRT groups. DESIGN, SETTING, AND PARTICIPANTS: Using the National Cancer Data Base, we identified men with unfavorable PCa treated between 2004 and 2012 with androgen suppression (AS) and either EBRT followed by LDR-B or DE-EBRT (75.6-86.4Gy). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Treatment selection was evaluated using logistic regression and annual percentage proportions. OS was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards, and propensity score matching. RESULTS AND LIMITATION: We identified 25038 men between 2004 and 2012, during which LDR-B boost utilization decreased from 29% to 14%. LDR-B was associated with better OS on univariate (7-yr OS: 82% vs 73%; p<0.001) and multivariate analyses (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.64-0.77). Propensity score matching verified an OS benefit associated with LDR-B boost (HR 0.74, 95% CI 0.66-0.89). The OS benefit of LDR-B boost persisted when limited to men aged <60 yr with no comorbidities. On subset analysis, there was no interaction between treatment and age, risk group, or radiation dose. Limitations include the retrospective design, nonrandomized selection bias, and the absence of treatment toxicity, hormone duration, and cancer-specific outcomes. CONCLUSIONS: Between 2004 and 2012, LDR-B boost utilization declined and was associated with better OS compared to DE-EBRT alone. LDR-B boost is probably the ideal treatment option for men with unfavorable PCa, pending long-term results of randomized trials. PATIENT SUMMARY: We compared radiotherapy utilization and survival for prostate cancer (PCa) patients using a national database. We found that low-dose rate brachytherapy (LDR-B) boost, a method being used less frequently, was associated with better overall survival when compared to dose-escalated external-beam radiotherapy alone for men with unfavorable PCa. Randomized trials are needed to confirm that LDR-B boost is the ideal treatment.
引用
- Johnson SB, Lester-Coll NH, Kelly JR, et al. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. Eur Urol. 2017. PMID: 28688613. doi:10.1016/j.eururo.2017.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。